Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27267830 | 0.89 | CHRNB2 (0.54) | CHRNB2CHRNA7CHRNA4CYP2A6HRH3 | |
| SCHEMBL2981954 | 0.80 | POLB (0.58) | CHRNB2CHRNA7CHRNA4CYP2A6HRH3 | |
| Hydrochloric Acid SCHEMBL3552773 | 0.79 | POLB (0.57) | CHRNB2CHRNA7CHRNA4CYP2A6HRH3 | |
| SCHEMBL17691524 | 0.78 | CHRNB2 (0.54) | TDP1L3MBTL1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL8667461 | 0.76 | POLB (0.57) | — | |
| SCHEMBL10601127 | 0.76 | POLB (0.61) | HRH1HRH3SLC6A2SLC6A4 | |
| SCHEMBL8658187 | 0.75 | HRH1 (0.81) | HRH1TDP1L3MBTL1TBXAS1CHRNA7 | |
| SCHEMBL29485667 | 0.75 | HRH1 (0.81) | HRH1TDP1L3MBTL1TBXAS1CHRNA7 | |
| SCHEMBL29485634 | 0.75 | HRH1 (0.81) | HRH1TDP1L3MBTL1TBXAS1CHRNA7 | |
| SCHEMBL2845851 | 0.75 | HRH1 (0.81) | HRH1TDP1L3MBTL1TBXAS1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10610526-B2 | Nicotine replacement therapy products comprising synthetic nicotine | Next Generation Labs, LLC (US) | 2020-04-07 | — | — | US | disclosed |
| US-20170189388-A1 | NICOTINE REPLACEMENT THERAPY PRODUCTS COMPRISING SYNTHETIC NICOTINE | PPM INVESTMENT GROUP CORP. | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189388-A1 | NICOTINE REPLACEMENT THERAPY PRODUCTS COMPRISING SYNTHETIC NICOTINE | NAPRT, NNT, NNMT | HRH1 1432/4885TDP1 1481/4885L3MBTL1 4050/4885 |
| US-10610526-B2 | Nicotine replacement therapy products comprising synthetic nicotine | NAPRT, NNT, NNMT | HRH1 1432/4885TDP1 1481/4885L3MBTL1 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.